



**HAL**  
open science

## The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy

Irene Pérez, Elena Campos-Pardos, Caridad Díaz, Santiago Uranga, Fadel Sayes, Francisca Vicente, Nacho Aguiló, Roland Brosch, Carlos Martín, Jesús Gonzalo-Asensio

### ► To cite this version:

Irene Pérez, Elena Campos-Pardos, Caridad Díaz, Santiago Uranga, Fadel Sayes, et al.. The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy. *Molecular Therapy - Nucleic Acids*, 2022, 27, pp.1235-1248. 10.1016/j.omtn.2022.02.011 . pasteur-03648358

**HAL Id: pasteur-03648358**

**<https://pasteur.hal.science/pasteur-03648358>**

Submitted on 21 Apr 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

# The *Mycobacterium tuberculosis* PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy

Irene Pérez,<sup>1,2,7</sup> Elena Campos-Pardos,<sup>1,2,7</sup> Caridad Díaz,<sup>3</sup> Santiago Uranga,<sup>1,2</sup> Fadel Sayes,<sup>4</sup> Francisca Vicente,<sup>3</sup> Nacho Aguiló,<sup>1,2</sup> Roland Brosch,<sup>4</sup> Carlos Martín,<sup>1,2,5</sup> and Jesús Gonzalo-Asensio<sup>1,2,6</sup>

<sup>1</sup>Grupo de Genética de Micobacterias, Departamento de Microbiología. Facultad de Medicina, Universidad de Zaragoza, IIS Aragón, C/Domingo Miral sn, 50019 Zaragoza, Spain; <sup>2</sup>CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Av. de Monforte de Lemos 5, 28029 Madrid, Spain; <sup>3</sup>Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Avenida del Conocimiento 34, 18016 Granada, Spain; <sup>4</sup>Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, CNRS UMR 3525, 25-28 Rue du Dr Roux, 75015 Paris, France; <sup>5</sup>Servicio de Microbiología Hospital Universitario Miguel Servet, Pº Isabel la Católica, 1-3, 50009 Zaragoza, Spain; <sup>6</sup>Instituto de Biocomputación y Física de Sistemas Complejos (BIFI), C/ Mariano Esquillor Gómez, Edificio I+D, 50018 Zaragoza, Spain

**Cyclic (di)nucleotides act as universal second messengers endogenously produced by several pathogens. Specifically, the roles of c-di-AMP in *Mycobacterium tuberculosis* immunity and virulence have been largely explored, although its contribution to the safety and efficacy of live tuberculosis vaccines is less understood. In this study, we demonstrate that the synthesis of c-di-AMP is negatively regulated by the *M. tuberculosis* PhoPR virulence system. Accordingly, the live attenuated tuberculosis vaccine candidate *M. tuberculosis* vaccine (MTBVAC), based on double *phoP* and *fadD26* deletions, produces more than 25- and 45-fold c-di-AMP levels relative to wild-type *M. tuberculosis* or the current vaccine bacille Calmette-Guérin (BCG), respectively. Secretion of this second messenger was exclusively detected in MTBVAC but not in *M. tuberculosis* or in BCG. We also demonstrate that c-di-AMP synthesis during *in vitro* cultivation of *M. tuberculosis* is a growth-phase- and medium-dependent phenotype. To uncover the role of this metabolite in the vaccine properties of MTBVAC, we constructed and validated knockout and overproducing/over-secreting derivatives by inactivating the *disA* or *cnpB* gene, respectively. All MTBVAC derivatives elicited superior interleukin-1 $\beta$  (IL-1 $\beta$ ) responses compared with BCG during an *in vitro* infection of human macrophages. However, both vaccines failed to elicit interferon  $\beta$  (IFN $\beta$ ) activation in this cellular model. We found that increasing c-di-AMP levels remarkably correlated with a safer profile of tuberculosis vaccines in the immunodeficient mouse model. Finally, we demonstrate that overproduction of c-di-AMP due to *cnpB* inactivation resulted in lower protection of MTBVAC, while the absence of c-di-AMP in the MTBVAC *disA* derivative maintains the protective efficacy of this vaccine in mice.**

ease, even if antimycobacterial drugs and a centenary vaccine named bacille Calmette-Guérin (BCG) exist.<sup>1</sup> According to the last World Health Organization report, more than 1.5 million people died from TB, and an estimated 10 million people fell ill with TB, in 2020.<sup>2</sup> At this point, it is key to remember that poverty-related pandemic diseases, such as TB, do not resemble the unprecedented fast development of vaccines against the current coronavirus disease 2019 (COVID-19) pandemic. Rather, after more than two decades, only three TB vaccine candidates have reached efficacy trials,<sup>3</sup> and none have been approved for emergency use authorization. Therefore, TB vaccines do not benefit from vaccine selection models such as those developed for COVID-19.<sup>4</sup> The *M. tuberculosis* infectious cycle usually starts when a few bacilli are inhaled by a susceptible host and, once in the lung, are phagocytosed by alveolar macrophages. The tubercle bacillus has evolved several mechanisms to avoid the cytotoxic arsenal of macrophages, whereby the induction of phagosomal membrane rupture is thought to allow translocation from the harsh phagolysosome environment to the gentler cytosol.<sup>5,6</sup> This process is mediated by ESAT-6, a protein with membranolytic activity,<sup>7</sup> which is secreted by the mycobacterial type VII secretion system named ESX-1 and acts in concert with the *M. tuberculosis* virulence lipid phthiocerol dimycocerosate (PDIM).<sup>8</sup> As a consequence, infected macrophages undergo apoptosis, which ultimately favors the cell-to-cell spread of *M. tuberculosis*.<sup>9</sup> The TB infectious cycle continues when an infected patient expels bacilli, typically by coughing, allowing the transmission of *M. tuberculosis* to an uninfected

Received 2 September 2021; accepted 11 February 2022;  
<https://doi.org/10.1016/j.omtn.2022.02.011>.

<sup>7</sup>These authors contributed equally


**Correspondence:** Jesús Gonzalo-Asensio, Grupo de Genética de Micobacterias, Departamento de Microbiología. Facultad de Medicina, Universidad de Zaragoza, IIS Aragón, C/Domingo Miral sn, 50019 Zaragoza, Spain.

**E-mail:** [jagonzal@unizar.es](mailto:jagonzal@unizar.es)

## INTRODUCTION

*Mycobacterium tuberculosis* is the causative agent of tuberculosis (TB), which is the main historic cause of death from an infectious dis-





**Figure 1. Characterization of c-di-AMP production and secretion in the live TB vaccines BCG and MTBVAC**

(A) Schematic representation of c-di-AMP synthesis and degradation steps in *M. tuberculosis* with indications of the genes involved in each enzymatic conversion. (B) Analysis of c-di-AMP present in whole-cell extracts (left panel) or secreted into the supernatants (right panel) of *M. tuberculosis* MT103, MTBVAC, BCG Pasteur, or BCG Danish. n.d., not detected. (C) Chromatogram showing the peak corresponding to the c-di-AMP metabolite (represented by an arrow) in 10-fold concentrated secreted fractions of *M. tuberculosis* MT103 and MTBVAC. Note that both diagrams are represented with different scales, and the detection of c-di-AMP is below the limit of detection (lod) in *M. tuberculosis* MT103 and in BCG (data not shown). (D) Comparison of c-di-AMP production in whole-cell extracts of *M. tuberculosis* MT103, MTBVAC, and BCG Pasteur grown in exponential and stationary cultures. (E) Comparison of c-di-AMP produced in whole-cell extracts of *M. tuberculosis* MT103 and MTBVAC during stationary growth in 7H9-rich media and in Sauton minimal media. Note that graphs in (D) and (E) are represented on a logarithmic scale. Data are the mean and standard deviation from at least three biological replicates.

individual. Deeper insights into the host-pathogen signaling activities that accompany this process are essential for a better understanding of the pathogen biology and the development of novel/alternative antimycobacterial therapies.

Nucleotide-derived molecules are produced by prokaryotic and eukaryotic organisms and serve as paradigm signaling mechanisms. Cyclic AMP (cAMP) and GMP (cGMP) have been studied for more than 50 years for their roles as second messengers, whereas the first knowledge on cyclic dinucleotides as signaling intermediates dates back to the discovery of c-di-GMP and c-di-AMP in 1987 and 2008, respectively.<sup>10,11</sup> In recent years, the roles of c-di-AMP as a second messenger in *Listeria monocytogenes*, *Bacillus subtilis*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, or *M. tuberculosis* and its essentiality in some of these pathogens have been gradually understood.<sup>12</sup> Altogether, the presence of this second

messenger and its essential synthesis by some bacteria highlight the importance of bacterial c-di-AMP for host-pathogen signaling. In this context, pioneering studies in *L. monocytogenes* demonstrated that this intracellular pathogen efficiently secreted c-di-AMP into the cytosol of host cells, which resulted in stimulation of stimulator of interferon genes (STING) and the subsequent activation of type I interferon (IFN) responses with the production of IFN $\beta$ .<sup>13,14</sup>

The synthesis of c-di-AMP in *M. tuberculosis* is catalyzed by the product of the Rv3586 gene (*disA*, also named *dacA*), a diadenylate cyclase that synthesizes c-di-AMP from 2 ATP molecules or, alternatively, 2 ADP molecules (Figure 1A).<sup>15</sup> The genome of *M. tuberculosis* also contains the Rv2837c (*cnpB*, also named *cdnP*) gene, which encodes a c-di-AMP phosphodiesterase that cleaves c-di-AMP into 2 AMP molecules (Figure 1A).<sup>16</sup> In sharp contrast to other pathogens, the c-di-AMP signaling mechanism is dispensable for *M. tuberculosis*

survival since both the *disA* and *cnpB* genes have been successfully inactivated, resulting in absent or increased *c*-di-AMP levels, respectively.<sup>15,16</sup> The secretion of *c*-di-AMP into the mycobacterial supernatant has been demonstrated only in *M. tuberculosis cnpB* knockout,<sup>16</sup> probably due to the larger amounts of *c*-di-AMP accumulated in this mutant, which suggests that wild-type *M. tuberculosis* possesses molecular tools to secrete this second messenger, albeit at levels beyond the technical limit of detection.

Similar to *L. monocytogenes*, the synthesis of *c*-di-AMP by *M. tuberculosis* elicits IFN $\beta$  responses by host macrophages in a STING-dependent manner.<sup>17</sup> Notably, the type I IFN responses were dependent on the bacterial *c*-di-AMP levels since the infection of macrophages with *disA*-knockout and *disA*-overexpressing mutants resulted in reduced or increased IFN responses, respectively. The abolition of bacterial *c*-di-AMP synthesis resulted in increased *M. tuberculosis* virulence, while *c*-di-AMP overexpression resulted in reduced virulence in murine infection models.<sup>17</sup> In addition, the production of IFN $\beta$  was independent of the host cyclic GMP-AMP synthase (cGAS), indicating that macrophages are able to sense the *c*-di-AMP produced by this pathogen when released into the cytosol.<sup>17</sup> The inactivation, or chemical inhibition, of *cnpB* resulted in virulence attenuation and higher type I IFN responses compared with the wild-type strain.<sup>16,18</sup> In addition to their ability to sense the *c*-di-AMP produced by intracellular pathogens, eukaryotic cells also are able to detect other microbial products, which then initiate cytosolic innate immune responses. It has been demonstrated that cytosolic sensing of *M. tuberculosis* DNA also drives type I IFN responses, and this phenotype is dependent on a functional ESX-1 system.<sup>19,20</sup>

Although the roles of *c*-di-AMP in the virulence or induction of innate immune responses against *M. tuberculosis* have been recently studied,<sup>16–20</sup> the contribution of mycobacterial *c*-di-AMP to the efficacy and level of attenuation of TB vaccines has been less explored. It is important to remember that of the different TB vaccine candidates in the pipeline, *c*-di-AMP is exclusively synthesized by live vaccines, which are limited to BCG (either as recombinant BCG or BCG revaccination strategies) or the attenuated *M. tuberculosis* vaccine MTBVAC.<sup>3</sup> The BCG vaccine was obtained a century ago after the *in vitro* culture passaging of a *Mycobacterium bovis* strain, the causative agent of bovine TB. During this *in vitro* subcultivation, BCG lost more than a hundred genes relative to *M. tuberculosis*.<sup>21</sup> The main genetic determinant of BCG attenuation is linked to the absence of RD1,<sup>22</sup> which corresponds to an  $\sim 9$  kb deletion in the ESX-1 locus, resulting in the loss of *esxA* (encoding the 6 kDa early secretory antigenic target ESAT-6) and flanking genes. On the other hand, MTBVAC was rationally attenuated by the deletion of the *phoP* and *fadD26* genes,<sup>23</sup> where PhoP is part of the two-component system PhoP-PhoR (PhoPR), which regulates *M. tuberculosis* virulence through three regulatory circuits.<sup>24</sup> Consequently, *M. tuberculosis phoP* and *phoPR* mutants (1) fail to secrete ESAT-6,<sup>25,26</sup> (2) do not synthesize acyltrehalose-derived lipids and sulfolipids,<sup>27,28</sup> and (3) secrete higher amounts of immunodominant antigens.<sup>29,30</sup> FadD26

is the first enzyme in a virulence gene cluster involved in the biosynthesis of PDIM.<sup>31</sup> Accordingly, the MTBVAC vaccine lacks PhoP- and PDIM-dependent virulence phenotypes.

Some studies have explored the role of *c*-di-AMP in BCG in relation to the interaction of this vaccine with immune cells and reported that a BCG strain overexpressing *c*-di-AMP induced higher IFN $\beta$  responses in murine macrophages than wild-type BCG did,<sup>17</sup> although the overall amounts of IFN $\beta$  measured in this assay were much lower than those reported from other IFN $\beta$ -induction studies using THP-1 macrophage-like cells.<sup>19,32</sup> Based on this observed difference, the authors tested the vaccine efficacy of wild-type BCG and *disA*-overexpressing BCG in a guinea pig vaccination model and found that guinea pigs vaccinated with BCG overexpressing *disA* showed lower pathology and lower bacterial loads upon challenge with *M. tuberculosis* compared with BCG-vaccinated animals.<sup>33</sup> In another study using BCG overexpressing *disA*, the authors found increased immune responses after mice were challenged with *M. tuberculosis*, even if the bacterial burdens in mouse organs were comparable between BCG- and BCG-*disA*-vaccinated animals.<sup>34</sup> These findings suggested a role for *c*-di-AMP in the vaccine properties of live attenuated vaccines, and accordingly, we sought to study the regulation and impact of the *c*-di-AMP second messenger on the attenuation and protective efficacy of the MTBVAC vaccine candidate.

## RESULTS

### The *c*-di-AMP second messenger is more highly produced and exclusively secreted by the MTBVAC vaccine compared with *M. tuberculosis* or BCG

We analyzed the presence of *c*-di-AMP in bacterial lysates of MTBVAC<sup>23</sup> and its parental strain named *M. tuberculosis* MT103, which is a clinical isolate belonging to the “modern” lineage 4.<sup>35</sup> As controls, we used two representative BCG strains: BCG Danish, which is licensed in Europe as a TB vaccine, and BCG Pasteur, the most widely used strain as a laboratory reference.<sup>21</sup> As testing conditions, we used exponential growth cultures using routine culture media for mycobacteria. Our results using whole-cell fractions demonstrated that even if *M. tuberculosis* MT103 and BCG produced *c*-di-AMP levels in the range of 5–8 ng/mL, the MTBVAC vaccine produced  $\sim 225$  ng/mL of this metabolite, which represents a 25- and 45-fold increase relative to *M. tuberculosis* and BCG, respectively (Figure 1B). Since the whole-cell lysates used in our experiments exclusively contain metabolites from bacterial pellets, we aimed to analyze the presence of *c*-di-AMP in bacterial supernatants, indicating efficient secretion of this second messenger. We failed to detect *c*-di-AMP above the limit of detection in *M. tuberculosis* and BCG, while we observed  $\sim 50$  ng/mL in the MTBVAC secreted fractions (Figure 1B). The absence of *c*-di-AMP secretion in *M. tuberculosis* and BCG was subsequently confirmed after concentrating 10-fold the bacterial supernatants prior to *c*-di-AMP measurements (Figure 1C). Previous studies also failed to detect the secretion of this second messenger in *M. tuberculosis*, even if they used an ELISA-based approach, in contrast to our spectrometric measurements.<sup>16,36</sup> Collectively, it is unclear whether yet unknown technical limitations exist

for the detection of this metabolite in the secreted fractions or whether *M. tuberculosis* exclusively secretes c-di-AMP under certain conditions. It is also possible that only specific *M. tuberculosis* strains are able to secrete c-di-AMP in detectable amounts. We tried to discard this latter assumption by assaying different *M. tuberculosis* strains in our study, but we should be aware that they do not represent the whole variability of *M. tuberculosis*. Nevertheless, our results suggest a direct correlation between intracellular production and the secretion of this molecule and agree with previous findings using an *M. tuberculosis* H37Rv *cnpB* mutant.<sup>16,36</sup> Notably, the detection of higher c-di-AMP secretion in MTBVAC was unexpected since this vaccine strain does not contain mutations in the c-di-AMP biosynthetic or degradation genes. Next, we analyzed the specific *in vitro* conditions leading to c-di-AMP synthesis and compared the c-di-AMP production in whole-cell fractions of exponential- or stationary-grown cultures. Both *M. tuberculosis* and MTBVAC produced higher amounts of this second messenger as bacterial growth progressed (Figure 1D), a finding also reproduced in *M. tuberculosis* CDC1551.<sup>17</sup> However, the BCG vaccine maintained equivalent c-di-AMP production irrespective of exponential or stationary growth. Second, we compared c-di-AMP production in rich (7H9) versus defined (Sauton) culture media during stationary growth. *M. tuberculosis* and MTBVAC produced lower levels of c-di-AMP in Sauton media than in 7H9 broth (Figure 1D). Altogether, these results suggest that the synthesis of c-di-AMP in the *M. tuberculosis* complex is a strain-, growth-phase-, and growth-medium-dependent phenotype.

#### Synthesis of c-di-AMP is a novel PhoPR-regulated phenotype in *M. tuberculosis*

The unexpected results of exacerbated amounts of c-di-AMP produced or secreted by MTBVAC relative to its parental *M. tuberculosis* MT103 (Figure 1) led us to study the mechanism responsible for this phenotype. MTBVAC carries two well-defined genetic deletions in the *phoP* and *fadD26* genes relative to its parental *M. tuberculosis* MT103 strain. To our knowledge, the *fadD26*-encoded gene product is exclusively involved in PDIM biosynthesis, and it seems unlikely to affect the synthesis of the c-di-AMP second messenger. However, PhoP acts as a transcription factor of the PhoPR two-component virulence system, which controls approximately 4% of the coding capacity of *M. tuberculosis*,<sup>29</sup> and we postulated that c-di-AMP synthesis might represent another PhoPR-regulated circuit. We used an *M. tuberculosis* *phoPR* mutant and a *phoPR*-complemented strain constructed in the H37Rv genetic background to confirm our hypothesis. Confirming the finding of higher c-di-AMP production in the MTBVAC vaccine, we observed higher amounts of c-di-AMP in whole-cell fractions of the *phoPR* mutant relative to the wild-type and complemented strains (Figure 2A). This result was also reproduced in the secreted fractions of the abovementioned strains (Figure 2B), indicating that c-di-AMP synthesis and secretion are negatively regulated by PhoP in *M. tuberculosis*. Intriguingly, most of the previously described PhoP-dependent phenotypes (ESAT-6 secretion, synthesis of acyltrehalose-derived lipids, or the control of a noncoding RNA that impacts antigen secretion) are positively regulated by PhoP, and


accordingly, this novel phenotype represents an exception to this rule. We also tried to identify the precise molecular mechanism underlying c-di-AMP regulation by PhoP. However, neither the *disA* nor the *cnpB* gene appeared differentially regulated in the H37Rv *phoPR* mutant or in the MTBVAC vaccine relative to their parental strains (Figure 2C). To examine whether the PhoPR system activates the transcription of proteins or other molecules that either degrade or inhibit the translation of enzymes related to c-di-AMP metabolism, we measured DisA and CnpB protein levels in *M. tuberculosis* H37Rv and its *phoPR* mutant by targeted multiple-reaction monitoring/mass spectrometry (MRM-MS). We analyzed and quantified five specific peptides of each protein to ensure the specific identification of both enzymes. Unexpectedly, DisA and CnpB protein levels showed nonsignificant differences between the wild type and the *phoPR* mutant, with average fold changes (WT/*phoPR*) of 0.88 and 0.87 for DisA and CnpB, respectively (Figures 2D and 2E). Taken together, our results rule out a PhoPR-dependent transcriptional or posttranscriptional mechanism over c-di-AMP metabolic enzymes. To our knowledge, there are no other genes described that are involved in c-di-AMP metabolism in *M. tuberculosis*, which may indicate that PhoPR regulates c-di-AMP synthesis and/or degradation by a yet-unknown mechanism. Interrogation of those PhoPR-regulated genes with hypothetical or unknown functions might help to identify novel players in the c-di-AMP metabolism of *M. tuberculosis*.

#### Genetic inactivation of *disA* and *cnpB* genes results in variable expression and secretion of c-di-AMP in the MTBVAC vaccine

To study the contribution of c-di-AMP synthesis to the vaccine phenotypes of MTBVAC, we constructed *disA* and *cnpB* knockouts in the MTBVAC vaccine strain by using the bacterial artificial chromosome (BAC)-recombineering strategy<sup>37</sup> to obtain  $\Delta disA::Km$  and  $\Delta cnpB::Km$  mutants (Figures 3A and 3B). After PCR confirmation of the recombinant colonies (Figures 3A and 3B), we analyzed the synthesis of c-di-AMP in these MTBVAC derivatives relative to the MTBVAC parent strain. Notably, the production of c-di-AMP in the whole-cell fraction of the *cnpB* mutant was as high as 23  $\mu\text{g}/\text{mL}$ , compared with 0.3  $\mu\text{g}/\text{mL}$  in the parental MTBVAC, which represents more than a 75-fold increase. As expected, we failed to detect c-di-AMP production in the MTBVAC *disA* mutant (Figure 3C). These phenotypes were then also evaluated for the secretion of c-di-AMP into the supernatant. As expected, we did not detect the secretion of c-di-AMP in the MTBVAC *disA* mutant, and the MTBVAC *cnpB* mutant secreted approximately 10 times more c-di-AMP than MTBVAC into the supernatant (Figure 3D). Accordingly, we obtained a set of MTBVAC vaccine candidate mutants that produced and secreted differential levels of c-di-AMP, which were used to characterize the role of this molecule in MTBVAC vaccine efficacy.

#### MTBVAC and BCG fail to induce an IFN $\beta$ response, but they successfully produce IL-1 $\beta$ in infected macrophages

Since bacterial-derived c-di-AMP is a well-known stimulator of STING,<sup>13,14</sup> we were prompted to study the type I IFN response elicited by the MTBVAC derivatives described in the previous section.




**Figure 2. Identification of PhoPR as a novel regulator of c-di-AMP synthesis and secretion in *M. tuberculosis***

(A) Production of c-di-AMP in whole-cell extracts of *M. tuberculosis* H37Rv, its  $\Delta$ phoPR mutant, and the mutant strain complemented (comp) with the *phoPR* genes. (B) Secretion of c-di-AMP into the supernatant of strains depicted in (A). Data are the mean and standard deviation from at least three biological replicates. (C) RNA sequencing (RNA-seq) profiles of three different genetic regions in *M. tuberculosis* MT103, MTBVAC, H37Rv, and the H37Rv  $\Delta$ phoPR mutant. The *disA*, *cnpB*, and *pks2* gene expression is indicated with a dashed box. Note that *disA* and *cnpB* show equivalent transcription levels in MTBVAC and the H37Rv  $\Delta$ phoPR mutant relative to their wild-type strains. In contrast, the *pks2* gene, which is a well-known PhoPR-regulated gene, shows downregulation in MTBVAC and the H37Rv  $\Delta$ phoPR mutant. (D) Quantification of DisA and CnpB protein levels in H37Rv and the H37Rv  $\Delta$ phoPR mutant by MRM-MS. Chromatograms show the identification of three different transitions from a specific peptide. Bars represent the area under the curve for every transition in H37Rv and the H37Rv  $\Delta$ phoPR mutant. Equivalent results were obtained for the DisA peptides ANVQLVPD-PSIPTDESGTR, HVLTDSATILSR, ANQAIATLER, and VFGYPTTTEAQDSTLSR and for the CnpB peptides VEVSFAAPATLPESLR, LGALGDLTDSGR, VLGSACLVS-EAVGGGR, and TVNLAAVASGFGGGGHR (data not shown).

Accordingly, we infected macrophages with MTBVAC, their *disA* and *cnpB* mutants, and BCG, and we measured the IFN $\beta$  produced by the cells. The existing literature indicates that mycobacteria must reach the cytosol to properly stimulate type I IFN responses. In this context, we should remember that BCG lacks a functional ESX-1 system due to RD1 deletion and that MTBVAC fails to secrete ESAT-6 because of *phoP* inactivation; accordingly, both vaccine strains and the *disA* or *cnpB* mutants are not expected to establish contact with the host cell cytosol. Consequently, we did not observe IFN $\beta$  induction upon infection with these vaccine strains (Figure 4A). Then, we used wild-type *M. tuberculosis* MT103 and H37Rv strains, which are known to rupture the phagosome, to confirm that both elicited a proper IFN $\beta$  response in our model (Figure 4A). Next, we demonstrated that macrophages infected with *M. tuberculosis* H37Rv  $\Delta$ RD1 (lacking a functional ESX-1 system due to a 9 kb deletion)<sup>38</sup> failed to induce IFN $\beta$  production, confirming the hypothesis that a functional ESX-1 system is essential to mount type I IFN responses against *M. tuberculosis* (Figure 4A). These results suggest that cytosolic contact is a prerequisite to stimulate STING,<sup>19,32,39</sup> whereby these findings disagree with the results of the previously mentioned study that reported IFN $\beta$  responses are elicited by BCG,<sup>17</sup> albeit at a low quantitative level. Taken together, these findings open the question of whether the contribution to STING stimulation exclusively de-

pends on bacterial DNA sensing via cGAS, as previously demonstrated,<sup>19,20</sup> or whether the endogenous c-di-AMP second messenger produced by *Mycobacterium* spp.<sup>17</sup> can also contribute to cytosolic responses against this pathogen.

In parallel, we analyzed the IL-1 $\beta$  responses in macrophages infected with the mycobacterial strains described above. Induction of IL-1 $\beta$  after BCG vaccination is associated with protective effects against related or unrelated bacterial and fungal pathogens<sup>40</sup> and hence constitutes a plausible mechanism to generate trained innate immunity in BCG and MTBVAC vaccines.<sup>40,41</sup> Remarkably, MTBVAC and its derived mutants elicited equivalent IL-1 $\beta$  responses to wild-type *M. tuberculosis*, and these responses were comparatively higher relative to BCG or *M. tuberculosis* H37Rv  $\Delta$ RD1 (Figure 4B). This result indicates that the absence of the ESX-1-encoding RD1 region in either BCG or *M. tuberculosis* H37Rv negatively impacts triggering complete IL-1 $\beta$  innate responses. Concerning the MTBVAC-derived strains, MTBVAC *cnpB* elicited lower IL-1 $\beta$  responses, while MTBVAC *disA* produced slightly higher IL-1 $\beta$  responses than MTBVAC (Figure 4B). This result might imply that type I IFN responses antagonize IL-1 $\beta$  production, as has been previously demonstrated during experimental infection with *M. tuberculosis*.<sup>42</sup>



**Figure 3. Construction and characterization of MTBVAC *disA* and MTBVAC *cnpB* mutants**

(A) Schematic representation of the construction of the MTBVAC *disA* mutant indicating the primers used to confirm the genetic deletion of *disA* by PCR. The lower panel shows PCR bands of  $\Delta disA::Km$  colonies indicative of a specific allelic exchange. (B) Schematic representation of the construction of the MTBVAC *cnpB* mutant indicating the primers used to confirm the genetic deletion of *cnpB* by PCR. The lower panel shows PCR bands of  $\Delta cnpB::Km$  colonies indicative of a specific allelic exchange. (C) Production of c-di-AMP in MTBVAC and its *disA* and *cnpB* mutant derivatives. (D) Secretion of c-di-AMP in MTBVAC and its *disA* and *cnpB* mutant derivatives. n.d., not detected. Data are the mean and standard deviation from three biological replicates.


### Differential levels of c-di-AMP produced by MTBVAC influence vaccine attenuation and protective efficacy

A recent study demonstrated that *disA* overexpression in BCG and the concomitant increase in c-di-AMP levels improved vaccine efficacy by triggering superior type I IFN responses in guinea pigs.<sup>33</sup> On the other hand, it is also possible that high c-di-AMP levels might be detrimental for the survival of a live vaccine by triggering a strong innate immune response. Considering the exacerbated c-di-AMP levels produced by the MTBVAC *cnpB* mutant compared with MTBVAC and the null production of c-di-AMP by the *disA* mutant (Figures 3C and 3D), we were prompted to check whether differential c-di-AMP synthesis might influence the vaccine properties of MTBVAC in the mouse model. We first measured the impact on virulence attenuation, a parameter related to the safety of a vaccine, by enumerating bacterial load in the lungs of severe combined immunodeficient (SCID) mice infected with BCG or the MTBVAC vaccine set. BCG resulted in a less attenuated vaccine, MTBVAC and MTBVAC *disA* showed intermediate attenuation, and MTBVAC *cnpB* was more attenuated (Figure 5A). Considering the absence of adaptive immunity in the SCID mice, these findings seem to support the hypothesis that the induction of potent innate immune responses, mediated by c-di-AMP cytosolic signaling, results in strong vaccine attenuation. In line with this observation, a previous study correlated BCG vaccine attenuation with protective efficacy, demonstrating that the more attenuated BCG strains resulted in less protection and vice

versa.<sup>43</sup> Then, we analyzed the protective efficacy of these vaccines using a challenge model with a virulent *M. tuberculosis* Beijing isolate. All vaccines protected against *M. tuberculosis*, but MTBVAC and MTBVAC *disA* showed better protection than BCG in the mouse model used. Conversely, MTBVAC *cnpB* displayed equivalent protection compared with BCG in our experimental model (Figure 5B). These results correlate with the attenuation profile of the MTBVAC set since MTBVAC and MTBVAC *disA* showed equivalent attenuation compared with the more attenuated MTBVAC *cnpB* mutant (Figure 5A). Altogether, we have started to elucidate the roles of c-di-AMP in TB vaccine safety and protective efficacy, but further work is needed in additional animal models to ascertain the precise contribution of this metabolite to the vaccine phenotypes of MTBVAC. In addition, nonspecific effects shown by BCG,<sup>44</sup> such as treatment of bladder cancer, protection against heterologous infections, therapeutic treatment of asthma, or potentiation of different immune responses, could also benefit from the modulation of c-di-AMP levels in MTBVAC-based vaccines.

### DISCUSSION

Cyclic (di)nucleotides constitute key second messengers in the microbial world, allowing not only intra- and interbacterial communication but also intracellular signaling in infected host cells.<sup>12,45</sup> In this study, we specifically focused on the role of c-di-AMP in *M. tuberculosis* in



**Figure 4. IFN $\beta$  and IL-1 $\beta$  responses during THP-1 macrophage infections with different MTBVAC derivatives**

(A) IFN $\beta$  produced by macrophages infected with the vaccines MTBVAC, its *disA* and *cnpB* mutants, and BCG Pasteur. *M. tuberculosis* MT103 and H37Rv strains and the *M. tuberculosis*  $\Delta$ RD1 mutant served as positive and negative controls of IFN $\beta$  production, respectively. (B) IL-1 $\beta$  produced after macrophage infection with the strains denoted in (A). Bars represent the mean and standard deviation from three cellular infections. Statistical analysis was performed using one-way ANOVA followed by Turkey's post-test. Asterisks indicate the following p values: \* 0.05 > p > 0.01; \*\* 0.01 > p > 0.0005; \*\*\*\* 0.0001 > p.

the context of vaccine attenuation and efficacy. When comparing the production of *c*-di-AMP in the existing two live vaccines in the TB vaccine pipeline, BCG and MTBVAC, we observed that MTBVAC unexpectedly produced higher *c*-di-AMP levels than BCG (Figure 1B). This phenotype was also translated to *c*-di-AMP secretion (Figures 1B and 1D), which revealed that *M. tuberculosis* possesses the mechanisms required to export this second messenger outside the bacterium, in agreement with previous studies.<sup>16,36</sup> Nevertheless, whether the *c*-di-AMP molecule is secreted by passive diffusion throughout the mycobacterial membrane or whether it is exported by a specific transporter remains to be elucidated.


Exploration of the molecular mechanism responsible for the increased production of *c*-di-AMP in MTBVAC demonstrated that the PhoPR two-component system negatively regulates the production of this metabolite in an *M. tuberculosis* clinical isolate (MT103) and in a widely used laboratory strain (H37Rv) since both the *M. tuberculosis* H37Rv *phoPR* mutant and the MTBVAC vaccine produced higher *c*-di-AMP levels than their respective wild-type strains (Figures 1 and 2). In addition, these results indicate that PhoPR-dependent synthesis of *c*-di-AMP is not related to the genetic background since MTBVAC and *M. tuberculosis phoPR* knockouts were constructed in unrelated parental strains. Furthermore, successful PhoPR complementation of *c*-di-AMP synthesis and secretion demonstrates that PhoPR, and not an unrelated mutation, is specifically responsible for this phenotype. Further work is needed to decipher the precise PhoPR-dependent mechanism leading to *c*-di-AMP regulation since both the synthetic and degrading enzymes of this metabolite are not differentially expressed in *phoP* or *phoPR* mutants (Figure 2C). In a previous study, we demonstrated that the secretion of immunodominant antigens in *M. tuberculosis phoPR* mutants<sup>30</sup> is indirectly regulated by a posttranscriptional mechanism involving the PhoPR-dependent noncoding RNA *mcr7*.<sup>29</sup> Thus, it is possible that *mcr7*, or other yet-unknown PhoPR-regulated noncoding RNAs, might exert posttranscriptional regulation over *c*-di-AMP synthesis in *M. tuberculosis*.

Since the *M. tuberculosis phoP* and *phoPR* mutants, as well as the MTBVAC vaccine, are attenuated in animal models,<sup>23,27,28,46,47</sup> we

can hypothesize that the high production of *c*-di-AMP in these strains might partly account for their attenuation. Indeed, *M. tuberculosis cnpB* mutants, known to produce and secrete high *c*-di-AMP levels, were reported to be more attenuated in murine infection models than the wild-type strain.<sup>16,18</sup> In this same line of evidence, the *M. tuberculosis disA* overexpression strain also produces increased amounts of *c*-di-AMP levels and shows a higher attenuation in mice than the parental strain.<sup>17</sup> Our findings that an MTBVAC *cnpB* mutant was more attenuated than MTBVAC in SCID mice (Figure 5A) further support the conclusion that *c*-di-AMP overproduction might contribute to stronger attenuation of *M. tuberculosis phoPR* mutants. We should remember that the PhoPR two-component system regulates many key virulence phenotypes in *M. tuberculosis*, including the secretion of ESAT-6. Thus, elucidating the precise contribution of increased *c*-di-AMP production to the attenuation of *phoP* and *phoPR* mutants is technically challenging. However, it has been demonstrated that MTBVAC elicits a clear dose-response induction of IL-1 $\beta$ , IL-6, IL-10, and tumor necrosis factor alpha (TNF- $\alpha$ ) in human monocytes,<sup>41</sup> and similar responses have also been observed upon infection with the attenuated strains *M. tuberculosis cnpB* mutant or *M. tuberculosis* overexpressing *disA*,<sup>17,18</sup> suggesting that a proper induction of innate immunity by high *c*-di-AMP amounts might result in better control of bacterial multiplication and consequently virulence attenuation.

Since the induction of IFN $\beta$  responses upon infection with BCG or BCG overexpressing *disA* has been previously demonstrated,<sup>17,33</sup> it is intriguing that we did not detect a dose-response induction of IFN $\beta$  responses upon infection of THP-1-differentiated macrophages with BCG, MTBVAC, MTBVAC *disA*, or MTBVAC *cnpB* mutants (Figure 4A).<sup>32</sup> However, it should be noted that different macrophages were used in both studies. While Dey et al. used mouse RAW264.7 cells and bone-marrow-derived macrophages, we used the THP1 macrophage cell line. In THP1 macrophages, virulent *M. tuberculosis* efficiently induced IFN $\beta$  responses, but this induction was strictly dependent on the presence of a completely functional RD1 region (Figure 5A). This result indicates that phagosomal escape might be essential to trigger the cytosolic surveillance pathway in





**Figure 5. Characterization of the impact of differential c-di-AMP production on MTBVAC vaccine attenuation and efficacy**

(A) Bacterial loads in the lungs of SCID mice after 4 weeks infected with BCG Pasteur, MTBVAC, and the MTBVAC *disA* and *cnpB* mutants. (B) Protective efficacy of BCG Pasteur, MTBVAC, and the MTBVAC *disA* and *cnpB* mutants in the C3H/HeNRj mouse model. Mice were immunized with the previously mentioned strains, left unvaccinated as a control, and challenged 8 weeks later with the *M. tuberculosis* Beijing W4 strain. Bacterial loads in the lungs were enumerated 4 weeks after the challenge as a measure of vaccine efficacy. All data are mean  $\pm$  SEM. Statistical analysis was performed by one-way ANOVA and the Bonferroni post hoc test.


these macrophages. However, the higher cytotoxic activity of RAW264.7 cells and bone-marrow-derived macrophages might result in IFN $\beta$  responses even in the absence of an intact RD1 region. A side-to-side comparison of IFN $\beta$  responses using different macrophage lines or primary cells would help to elucidate the precise roles of c-di-AMP and the RD1 region in triggering cytosolic surveillance responses.

Despite the macrophage infections with MTBVAC, and the MTBVAC *disA* or the MTBVAC *cnpB* mutants not resulting in differential IFN $\beta$  immune responses (Figure 4), the production and secretion of variable c-di-AMP levels by our vaccine set have an impact on vaccine attenuation and efficacy (Figure 5). The exacerbated c-di-AMP amounts produced by the MTBVAC *cnpB* mutant otherwise results in higher vaccine attenuation (Figure 5A). One possible explanation for this phenotype could be that the robust induction of intracellular surveillance responses otherwise results in better control of bacterial multiplication in the lung. In agreement with a previous observation,<sup>43</sup> the overattenuation of a vaccine is associated with lower protective efficacy, as observed with the MTBVAC *cnpB* mutant (Figure 5B). Nevertheless, it was previously demonstrated that BCG overexpressing *disA* exhibits superior efficacy to BCG in the guinea pig challenge model.<sup>33</sup> In terms of c-di-AMP production, both the MTBVAC *cnpB* mutant and the recombinant BCG overexpressing *disA* are able to produce increased c-di-AMP levels relative to their parental strains, and consequently, the opposing results in protective efficacy upon vaccination with both strains is unexpected. Several explanations exist for this discrepancy. First, different animal models were used in both experiments, and the mouse model does not necessarily reflect the more sensitive guinea pig model used in Dey et al. Second, different challenge strains were used in these studies. While Dey et al. used the *M. tuberculosis* H37Rv laboratory strain, we used *M. tuberculosis* W4, which is known to belong to the Beijing hypervirulent family. Third, it remains to be determined whether the MTBVAC *cnpB* mutant and the BCG overexpressing *disA* produce equivalent c-di-AMP levels since we should remember that MTBVAC and MTBVAC *cnpB* produce much greater quantities of this second

messenger relative to BCG. Fourth, to our knowledge, there is no evidence of c-di-AMP secretion in BCG since a BCG *cnpB* mutant failed to reproduce secretion of this metabolite compared with an *M. tuberculosis* *cnpB* mutant.<sup>36</sup> Taken together, these technical differences might very well account for the different results in vaccine efficacy.

In the context of TB vaccines, an unresolved question regarding host cytosolic signaling refers to the access of the c-di-AMP produced by live vaccines to the host cell cytosol to stimulate STING. Previous studies demonstrated that *M. tuberculosis* efficiently stimulates STING in a process dependent on functional ESX-1.<sup>19,20</sup> However, it is key to remember that neither BCG nor MTBVAC vaccines secrete ESAT-6, and consequently, these vaccines do not have access to the cytosol, as *M. tuberculosis* does.<sup>5</sup> Thus, the induction of IFN $\beta$  responses by BCG or BCG overexpressing *disA* is puzzling.<sup>17</sup> It is possible that endogenous c-di-AMP produced by BCG freely traverses the eukaryotic membrane of the phagolysosome, as has been reported with other cyclic dinucleotides.<sup>48,49</sup> This hypothesis would explain a direct STING stimulation by vaccine-produced c-di-AMP in the absence of a functional ESX-1 system and would pave the way to improving live TB vaccines.

The question of whether induction of the host cytosolic surveillance with production of IFN $\beta$  is beneficial or detrimental to viral or bacterial pathogens is still a matter of debate.<sup>50,51</sup> The factors that determine whether this response is protective or pathogenic have yet to be defined, and frequently, the answer depends on the experimental model, the pathogen itself, or the specific stage at which IFN $\beta$  responses are produced. Considering the coexistence of c-di-AMP synthetic and degradation pathways in *M. tuberculosis*, this might represent an evolutionary mechanism to manipulate the host response in favor of the pathogen. While c-di-AMP endogenously produced by *M. tuberculosis* triggers the host cytosolic surveillance pathway, which is probably detrimental for bacterial survival, the TB bacillus also possesses a c-di-AMP phosphodiesterase that contributes to alleviating this detrimental effect. We should remember



**Figure 6. Schematic representation of the PhoPR-related phenotypes in *M. tuberculosis* (left side) and MTBVAC (right side) in the context of the macrophage environment**

Until the publication of this manuscript, three virulence networks were documented to be regulated by PhoPR in *M. tuberculosis*: the synthesis of di- and poli-acyltrehaloses (DAT and PAT, respectively) and sulfolipid (SL), the latter lipid being involved in the inhibition of innate immunity and the production of cough; the secretion of ESAT-6, which mediates phagosomal rupture and the consequent cytosolic escape; and the downregulation of TatC, known to be an essential constituent of the twin arginine translocation (TAT), which results in restrained antigen secretion. These phenotypes are inactivated in MTBVAC because of a *phoP*-inactivating mutation and result in a lack of PhoPR-regulated lipids, the absence of ESAT-6 secretion, and increased secretion of TAT substrates. We demonstrate here that, in addition to the aforementioned phenotypes, *c*-di-AMP synthesis and secretion are negatively regulated by PhoPR in *M. tuberculosis*. Accordingly, the high *c*-di-AMP levels in the MTBVAC vaccine result in enhanced innate immune responses.

that the *M. tuberculosis* PhoPR virulence system activates many phenotypes required for *M. tuberculosis* virulence. PhoPR allows ESAT-6 secretion<sup>25</sup> and subsequent cytosolic escape,<sup>5</sup> which ultimately favors the cell-to-cell spread of *M. tuberculosis*.<sup>9</sup> In addition, PhoPR controls the synthesis of acyltrehalose-derived lipids and sulfolipids,<sup>27,47</sup> which inhibits the innate immune response<sup>52</sup> and induces a productive cough,<sup>53</sup> facilitating transmission to uninfected individuals. Finally, PhoPR activates transcription of a noncoding RNA that downregulates secretion of immunodominant antigens,<sup>29</sup> thus decreasing immune recognition (Figure 6).<sup>30</sup> In line with these observations, our demonstration that *c*-di-AMP synthesis is repressed by the PhoPR virulence system reinforces the hypothesis that production of this second messenger is detrimental to *M. tuberculosis*. Therefore, it is tempting to speculate that *M. tuberculosis* has evolved two complementary pathways to restrain *c*-di-AMP levels: the capacity to degrade this metabolite through CnpB phosphodiesterase and the repression of *c*-di-AMP synthesis by PhoPR. Both mechanisms would

contribute to diminished recognition of *M. tuberculosis* by the host cytosolic surveillance system (Figure 6).

A previous study demonstrated that a tuberculosis subunit vaccine adjuvant with a synthetic cyclic-dinucleotide analog conferred enhanced protection and superior Th1 and Th17 responses compared with BCG vaccination.<sup>54</sup> This finding highlights the relevance of cyclic dinucleotides as vaccine adjuvants and opens perspectives to rationally engineer live vaccines. In this study, we attempted to provide knowledge to unresolved questions concerning the role of this second messenger in the TB vaccine field. Inactivation of *phoP* in MTBVAC results in unrestrained *c*-di-AMP synthesis and enhanced stimulation of innate immunity relative to BCG. Altogether, our research has paved the way to modulate endogenous *c*-di-AMP production by live attenuated TB vaccines as a strategy to treat not only infectious diseases but also diseases with an immunological component.

**Table 1. Mycobacterial strains used in this study**

Strain designation	Description	Reference
Mt103	clinical isolate of <i>M. tuberculosis</i> lineage 4	Jackson et al. <sup>55</sup>
H37Rv	reference laboratory strain of <i>M. tuberculosis</i>	Cole et al. <sup>56</sup>
H37Rv $\Delta$ phoPR	mutant of <i>phoP</i> and <i>phoR</i> genes in H37Rv	Gonzalo-Asensio et al. <sup>47</sup>
H37Rv $\Delta$ phoPR complemented	complemented <i>phoPR</i> genes in H37Rv $\Delta$ phoPR strain	Gonzalo-Asensio et al. <sup>47</sup>
H37Rv $\Delta$ RD1	H37Rv deleted RD1 region	Pym et al. <sup>22</sup>
BCG Pasteur	current vaccine against TB, attenuated from <i>M. bovis</i>	Brosch et al. <sup>21</sup>
BCG Danish	current vaccine against TB, attenuated from <i>M. bovis</i>	Brosch et al. <sup>21</sup>
MTBVAC::hyg (Mt103 $\Delta$ fadD26 $\Delta$ phoP::hyg)	double marked mutant in <i>phoP</i> with <i>res-Qhyg-res</i> cassette	Arbues et al. <sup>23</sup>
MTBVAC	double unmarked mutant of <i>phoP</i> and <i>fadD26</i> in Mt103 strain	Arbues et al. <sup>23</sup>
MTBVAC $\Delta$ cnpB::km	marked mutant of <i>cnpB</i> gene in MTBVAC	this study
MTBVAC $\Delta$ disA::km	marked mutant of <i>disA</i> gene in MTBVAC	this study

## MATERIAL AND METHODS

### Bacterial strains and growth conditions

We used the *M. tuberculosis* strain H37Rv, its *phoPR* mutant and the complemented strain Mt103, and H37Rv  $\Delta$ RD1. We also used the vaccine strain MTBVAC and its derivatives MTBVAC  $\Delta$ cnpB::Km and MTBVAC  $\Delta$ disA::Km, as well as BCG Pasteur and BCG Danish. These strains are further described in Table 1. Mycobacteria were cultured in Middlebrook 7H9 liquid medium (Difco) containing 0.05% Tween 80 and supplemented with 10% (vol/vol) ADC or dextrose/NaCl. For solid media, Middlebrook 7H10 broth containing 10% (vol/vol) ADC was used. When necessary, 20  $\mu$ g/mL hygromycin (Hyg) or 20  $\mu$ g/mL kanamycin (Km) was added to the media. *Escherichia coli* was cultured in liquid media Luria-Bertani (LB) broth or in solid media LB agar. When required, media were supplemented with 100  $\mu$ g/mL ampicillin (Amp), 12.5  $\mu$ g/mL chloramphenicol (Cm), 20  $\mu$ g/mL Km, or 50  $\mu$ g/mL Hyg.

### Construction of *cnpB* and *disA* mutants in MTBVAC

Deletion of the *cnpB* or *disA* genes in MTBVAC was obtained using the BAC-rec strategy.<sup>37</sup> An *M. tuberculosis* H37Rv BAC library was constructed in the pBeloBAC11 vector and contained in *E. coli* DH10B.<sup>57</sup> The thermosensitive plasmid pKD46 (containing the red recombinase from lambda phage) was transformed into the DH10B clone carrying Rv404 (containing the *cnpB* gene) and Rv222 (containing the *disA* gene).<sup>58</sup> *E. coli* strains carrying the BAC Rv404 or Rv222 and pKD46 plasmids were cultured in media in the presence of 0.15% arabinose and transformed with a PCR product containing a Km-resistant cassette from pKD4 flanked by 40 bp identity arms to target

the gene of interest. PCR products were obtained using *cnpB*-P1-Fw/*cnpB*-P2-Rv and *disA*-P1-Fw/*disA*-P2. Recombinants were selected in LB plates containing Km, and gene deletion in the BAC was confirmed by PCR using specific primers (Table 2).

Allelic exchange substrates (AESs) containing a Km-resistant cassette flanked by 1.1 kb identity arms for site-specific recombination were obtained by PCR using BAC Rv404- $\Delta$ cnpB::Km and Rv222- $\Delta$ disA::Km templates and *cnpB*-KO-Fw/*cnpB*-KO-Rv and *disA*-KO-Fw/*disA*-KO-Rv primers. AESs were transformed in MTBVAC carrying pJV53H and cultured in the presence of 0.2% acetamide.<sup>59</sup> Recombinants were selected in 7H10 plates containing Km and confirmed using specific primers. The sequences of the primers used for knockout construction and verification are provided in Table 2.

### Metabolite extraction

Mycobacterial strains were cultured until log-phase (OD<sub>600 nm</sub> ~0.6) in 7H9 medium supplemented with ADC or dextrose/NaCl to measure c-di-AMP production or secretion, respectively. To quantify c-di-AMP in the secreted fraction, cultures were centrifuged, and supernatants were filtered through a 0.22  $\mu$ m pore-size filter and used for metabolite quantification. To quantify c-di-AMP produced by bacteria in the whole-cell fraction, bacterial pellets were resuspended in 300  $\mu$ L extraction solution (acetonitrile/methanol/water, 2/2/1, vol/vol/vol, high-performance liquid chromatography [HPLC] grade) and transferred to tubes containing glass beads (MP Biomedicals). Mycobacterial suspensions were disrupted by FastPrep (6.5 m/s, 45 s), incubated on ice for 15 min, and heated at 95°C for 10 min. Suspensions were cooled on ice, and supernatants were transferred into a new vial after centrifugation at 14,000 RPM at 4°C for 10 min. Two additional extractions were performed by the addition of 200  $\mu$ L to the tubes containing glass beads. Suspensions were disrupted by Fast-Prep (6.5 m/s, 45 s) and incubated on ice for 15 min, and supernatants were combined into vials after centrifugation (14,000 RPM, at 4°C for 10 min). Vials containing the supernatants were stored overnight at -20°C. The day after, vials were centrifuged at 14,000 RPM for 10 min at 4°C, and supernatants were filtered through a 0.22  $\mu$ m pore-size filter to quantify c-di-AMP in whole-cell lysates.

### c-di-AMP quantification

Quantification of total c-di-AMP and c-di-GMP of the H37Rv, H37Rv  $\Delta$ phoPR, H37Rv  $\Delta$ phoPR complemented strain, Mt103, and MTBVAC strains was performed in collaboration with the Institute of Pharmacology, Hannover Medical School, Hannover (Germany) as described in Corrigan et al.<sup>60</sup> These measurements were performed using isotope-labeled <sup>13</sup>C<sup>15</sup>N of c-di-AMP. The same extractions were also quantified in the proteomics facility of Servicios Científico Técnicos of CIBA (IACS-Universidad de Zaragoza) using c-di-GMP as an internal control because our previous finding demonstrated a lack of production of this metabolite in *M. tuberculosis*. Briefly, c-di-AMP quantification (LC-ESI-MS/MS) was performed on an Agilent 1200 HPLC and a 4000 QTRAP mass spectrometer (SCIEX), column Clarity 3  $\mu$ m Oligo-RP 100  $\times$  2 mm (Phenomenex). Eluents

**Table 2. Primers used in this study**

Primers	Sequence 5–3
cnpB-P1-Fw	GGGTGCGCAAGCGGGTAGAGGTC AGCTTTCGCGCGCCGGGTGT AGGCTGGAGCTGCTTC
cnpB-P2-Rv	GCGTCGTCGATCGAGCCGG TGGTCGTATACCCCGCGGC CACATATGAATATCCTCCTTAGT
KO-cnpB-Fw	GGCGGTTGTTCGGTCTCTCG
KO-cnpB-Rv	CCTAGCCCTAACGCCGCTG
Confirm-KO-cnpB-Fw	GCGGTGATCATCGGTTTCAATGTGCG
Confirm-KO-cnpB-Rv	CAACGCACTCGCCACCGTC
cnpB-I1	GGGCGATCTAACTGATCCGGGC
cnpB-I2	CGACCTCCTGAACACCGCCG
disA-P1-Fw	GCACGCTGTGACTCGTCCGACCTGC GTGAGGCTGTGCGCGTGTAGGCT GGAGCTGCTTC
disA-P2-Rv	CGTCCGACAGGGCGTCCAGTTCGT CCAGGGTGGCATTGATCATATGAAT ATCCTCCTTAGT
KO-disA-Fw	CTCGCCGACAGTCCGAC
KO-disA-Rv	GATCGCGGTGCCATCGTCATC
Confirm-KO-disA-Fw	GCGCGCTCTATGTCTCTGGTGAG
Confirm-KO-disA-Rv	CGTTTGCCTGACCTGGCCCTAC
disA-I1	GATGGTGGCTTCTCCCTCGATGTC
disA-I2	CACCACCGTCATCACATCGCG
P1-inv	GAAGCAGCTCCAGCCTACAC
P2-inv-long	CTTCGGAATAGGAACTAAG GAGGATATTCATATG

used included: Phase A, 50 mM TEAA, and eluent B methanol. *c*-di-GMP was used as the internal standard. A calibration curve was obtained from 1 to 3,000 ng/mL. Samples were incubated at 45°C for 90 min and resuspended in a specific volume of 10 mM TEAA and *c*-di-GMP (400 ng/mL). Solutions were vortexed, sonicated for 5 min, vortexed again, and filtered through a 0.45 µm pore size. The injection volume was 25 µL, and the flow rate was 200 µL/min throughout the chromatographic run. Also, 95% A and 5% B were used from 0 to 5 min, followed by a linear gradient from 95% A to 30% A for 9 min, followed by 9 min until 95% A and 5% B. The detection method was selected reaction monitoring (SRM). All secreted fractions were evaluated in collaboration with Fundación MEDINA, Granada (Spain). The equipment used was an LC Agilent 1290 coupled to an API 4000 mass spectrometer (SCIEX) and an automated CTC PAL injector. The chromatographic column was Xbridge BEH amide, with dimensions of 100 × 2.1 mm and 3.5 µm (Waters). The injection volume was 7 µL, and the chromatographic run was 7.1 min. Mobile phase A consisted of deionized water (0.1% ammonia), and mobile phase B consisted of acetonitrile (0.1% ammonia) with a gradient flow rate of 300 µL/min. The gradient elution was performed as follows: *t* = 0.0–0.50 min 95% B; *t* = 0.50–4.50 min 30% B; *t* = 4.50–5.70 min 30% B; *t* = 5.70–5.80 min

95% B; *t* = 5.80–7.10 min 95% B. For the analysis, *c*-di-GMP was used as the internal standard. The standards for the calibration curve were obtained by adding *c*-di-AMP (14.7 to 1,890 ng/mL). In the samples, the internal standard was also added (100 ng/mL), and 200 µL of acetonitrile 0.1% formic acid was added, vortexed, and centrifuged (5 min, 3,700 RPM at 4°C). The concentration of the analyte was obtained using the calibration curve and the relation of the analyte area and the internal standard area. The limit of detection (lod) of *c*-di-AMP in the technique was 5 ng/mL, equivalent to 7.6 nM of pure compound.

### Protein identification by MRM/MS

The MRM assay approach was applied for the measurement of specific DisA and CnpB peptides in whole-cell extracts of H37Rv and its *phoPR* mutant. Bacterial cultures (20 mL) were grown to an OD (600 nm) of 0.6 and pelleted. Bacterial pellets were resuspended in 2 mL Tris-HCl 100 mM and disrupted in FastPrep (2 cycles, 45 s at speed 6.5 m/s, samples were cooled on ice between cycles). Tubes were centrifuged, and the aqueous phases containing whole-cell protein were filtered through a 0.22 µm filter. For in-solution digestion, protein was resuspended in denaturing buffer (6 M urea, 100 mM Tris-HCl pH 7.8). Cysteines were reduced with 200 mM DTT for 30 min at 37°C and alkylated with 200 mM iodoacetamide for 30 min in the dark. Unreacted iodoacetamide was consumed by adding an excess of the reducing agent (200 mM DTT) for 30 min at room temperature. Samples were diluted with 50 mM ammonium bicarbonate to a final concentration of less than 1 M urea. Protein digestion was carried out with trypsin (Trypsin Gold, Promega) at a 1:20 ratio (enzyme/protein) for 18 h at 37°C. The reaction was stopped by adding concentrated formic acid (Sigma). Samples were dried in a vacuum concentrator and reconstituted in 98% H<sub>2</sub>O, 2% acetonitrile, and 0.1% formic acid.

Protein identification was performed on a triple quadrupole/linear ion trap mass spectrometer QTRAP 6500+ (SCIEX, Foster City, CA, USA) coupled to nano/micro-HPLC (Eksigent LC 425, SCIEX). Sample preconcentration and desalting of tryptic digests were performed on a C18 column (Luna 0.3 mm id, 20 mm, 5 µm particle size, Phenomenex, Torrance, CA, USA). Tryptic peptides were then separated using a C18 column (Luna Omega Polar 0.3 mm id, 150 mm, 3 µm particle size, Phenomenex, Torrance, CA, USA) at a flow rate of 5 µL/min, with a 30 min linear gradient from 5 to 35% acetonitrile in 0.1% formic acid. The mass spectrometer was interfaced with a microspray source (Turbo V) equipped with an uncoated fused silica emitter tip (25 µm inner diameter, 10 µm tip, New Objective, Woburn, MA, USA) and was operated in positive ion mode. MS source parameters were as follows: capillary voltage 5,000 V, source temperature 150°C, declustering potential (DP) 85 V, curtain, ion source gas (nitrogen) 25 psi, and collision gas (nitrogen) 15 psi. Analyses were performed using an information-dependent acquisition (IDA) method with the following steps: single enhanced mass spectra (EMS, 400–1,400 *m/z*), from which the most intense peaks were subjected to an enhanced product ion (EPI [MS/MS]) scan. Peptide identity was confirmed using an MRM-initiated detection and sequencing

(MIDAS) algorithm using Mascot (v.2.3, Matrix Science, UK) and Swiss-Prot. The identified and quantified peptides were as follows: for DisA, ANVQLVDPDSIPTDESGTR, HVLTDSATILSR, ANQAIATLER, LQLDELLGGNDTAR, and VFGYPTTTEAQDSTLSPR and for CnpB, VEVSFAAPATLPESLR, LGALGDLTDSGR, LVEIGVDNATVSR, VLGSAQLVSEAVGGR, and TVNLAAVASGFGG GGHR.

### Mycobacterial infection of THP-1

THP-1 cells were grown in RPMI 1640 GlutaMAX medium supplemented with 10% (vol/vol) decomplexed and filtrated fetal bovine serum (FBS). THP-1 monocytes were differentiated into macrophages by adding 10 ng/mL PMA for 72 h. Cells were distributed in a 24-well plate (500,000 cells per well), and mycobacteria strains were added at a multiplicity of infection (MOI) of 5:1. For bacteria preparation, cultures were centrifuged, and pellets were resuspended in 5 mL of 1× DPBS. OD was measured to calculate the volume required. Bacteria were added to THP-1 cells and incubated at 37°C and 5% CO<sub>2</sub>. Supernatants were collected after 24 h and filtered through a 0.22 μm pore-size filter. IL-1β and IFNβ released were detected by ELISA. Human IL-1β/IL-1F2 and IFNβ released by THP-1 macrophages were quantified using the DY201-05 (R&D Systems) and DY814-05 (R&D Systems) kits, respectively.

### Mouse experiments

All mice were observed and kept under controlled conditions. For attenuation experiments, MTBVAC, MTBVAC  $\Delta$ cnpB::Km, MTBVAC  $\Delta$ disA::Km, or BCG Pasteur was inoculated with 10<sup>5</sup> CFU contained in 40 μL of PBS by the intranasal route in immunocompromised SCID mice. The bacterial burden in the lungs was assessed 4 weeks postinoculation by enumerating colonies grown in 7H10-ADC plates. For protection experiments, C3H/HeNRj female mice were subcutaneously vaccinated with 10<sup>6</sup> CFU in 100 μL PBS containing each of the abovementioned strains or left unvaccinated as a control group. Eight weeks later, the mice were challenged by the intranasal route with 200 CFU in 40 μL PBS of the *M. tuberculosis* W4 strain. Four weeks postchallenge, the bacterial burden was evaluated in the lungs by inoculating serial dilutions onto 7H10-ADC plates.

### Ethics statement

Experimental animal studies were performed in agreement with European and national directives for the protection of animals for experimental purposes. All procedures were carried out under Project License PI46/18, approved by the Ethics Committee for Animal Experiments from the University of Zaragoza.

### ACKNOWLEDGMENTS

The authors would like to acknowledge Prof. Volkhard Kaever from the Hannover Medical School and Irene Orera from the Proteomics Platform of Servicios Científico Técnicos del CIBA (IACS-Universidad de Zaragoza), ProteoRed-ISCI member, for helping us with c-di-AMP quantification. We also acknowledge the use of Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza.

Finally, we offer our special recognition to Prof. Iñigo Lasa from Navarrabiomed for his guidance during this project. This work was supported by a grant from the Spanish Ministry of Science and Innovation to J.G.-A. (reference PID2019-104690RB-I00). I.P. was a recipient of a “DGA-Fondo Social Europeo” grant. I.P. also was a recipient of a “Programa CAI-Ibercaja Estancias de Investigación” grant (CM3/18) and a “FEMS Research and Training” grant (FEMS-GO-2018-118) to perform an internship at the Integrated Mycobacterial Pathogenomics Unit at the Institut Pasteur of Paris. MEDINA authors disclosed the receipt of financial support from Fundación MEDINA, a public-private partnership of Merck Sharp & Dohme de España S.A./Universidad de Granada/Junta de Andalucía (PIN-0474-2016).

### AUTHOR CONTRIBUTIONS

Conceptualization, J.G.-A., C.M., and I.P.; methodology, J.G.-A., C.M., R.B., N.A., C.D., F.V., F.S., S.U., and I.P.; experimental research, J.G.-A., C.D., F.S., S.U., E.C.-P., and I.P.; writing – original draft, J.G.-A. and I.P.; writing – review & editing, J.G.-A.; funding acquisition, J.G.-A.; supervision, J.G.-A., C.M., R.B., and F.V. All authors reviewed the final report.

### DECLARATION OF INTERESTS

C.M. and J.G.-A. are coinventors on the patent “Tuberculosis vaccine”. N.A., C.M., and J.G.-A. are coinventors on the patent “Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients”. Both patents were filed by the University of Zaragoza.

### REFERENCES

- Paulson, T. (2013). Epidemiology: a mortal foe. *Nature* 502, S2–S3. <https://doi.org/10.1038/502S2a>.
- WHO (2021). *Global Tuberculosis Report*.
- Martin, C., Aguilo, N., Marinova, D., and Gonzalo-Asensio, J. (2020). Update on TB vaccine pipeline. *Appl. Sci.* 10, 15. <https://doi.org/10.3390/app10072632>.
- Abdelwahab, S.F., Issa, U.H., and Ashour, H.M. (2021). A novel vaccine selection decision-making model (VSDMM) for COVID-19. *Vaccines (Basel)* 9. <https://doi.org/10.3390/vaccines9070718>.
- van der Wel, N., Hava, D., Houben, D., Fluitsma, D., van Zon, M., Pierson, J., Brenner, M., and Peters, P.J. (2007). M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. *Cell* 129, 1287–1298. <https://doi.org/10.1016/j.cell.2007.05.059>.
- Simeone, R., Sayes, F., Lawaree, E., and Brosch, R. (2021). Breaching the phagosome, the case of the tuberculosis agent. *Cell Microbiol.* 23, e13344. <https://doi.org/10.1111/cmi.13344>.
- Houben, D., Demangel, C., van Ingen, J., Perez, J., Baldeon, L., Abdallah, A.M., Caleechurn, L., Bottai, D., van Zon, M., de Punder, K., et al. (2012). ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. *Cell Microbiol.* 14, 1287–1298. <https://doi.org/10.1111/j.1462-5822.2012.01799.x>.
- Augenstein, J., Arbués, A., Simeone, R., Haanappel, E., Wegener, A., Sayes, F., Le Chevalier, F., Chalut, C., Malaga, W., Guillhot, C., et al. (2017). ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. *Cell Microbiol.* 19. <https://doi.org/10.1111/cmi.12726>.
- Aguilo, J.I., Alonso, H., Uranga, S., Marinova, D., Arbués, A., de Martino, A., Anel, A., Monzon, M., Badiola, J., Pardo, J., et al. (2013). ESX-1-induced apoptosis is involved

- in cell-to-cell spread of *Mycobacterium tuberculosis*. *Cell Microbiol.* 15, 1994–2005. <https://doi.org/10.1111/cmi.12169>.
10. Ross, P., Weinhouse, H., Aloni, Y., Michaeli, D., Weinberger-Ohana, P., Mayer, R., Braun, S., de Vroom, E., van der Marel, G.A., van Boom, J.H., and Benziman, M. (1987). Regulation of cellulose synthesis in *Acetobacter xylinum* by cyclic diguanylic acid. *Nature* 325, 279–281. <https://doi.org/10.1038/325279a0>.
  11. Witte, G., Hartung, S., Buttner, K., and Hopfner, K.P. (2008). Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates. *Mol. Cell.* 30, 167–178. <https://doi.org/10.1016/j.molcel.2008.02.020>.
  12. Corrigan, R.M., and Grundling, A. (2013). Cyclic di-AMP: another second messenger enters the fray. *Nat. Rev. Microbiol.* 11, 513–524. <https://doi.org/10.1038/nrmi-cro3069>.
  13. Woodward, J.J., Iavarone, A.T., and Portnoy, D.A. (2010). c-di-AMP secreted by intracellular *Listeria monocytogenes* activates a host type I interferon response. *Science* 328, 1703–1705. <https://doi.org/10.1126/science.1189801>.
  14. Sauer, J.D., Sotelo-Troha, K., von Moltke, J., Monroe, K.M., Rae, C.S., Brubaker, S.W., Hyodo, M., Hayakawa, Y., Woodward, J.J., Portnoy, D.A., and Vance, R.E. (2011). The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to *Listeria monocytogenes* and cyclic dinucleotides. *Infect. Immun.* 79, 688–694. <https://doi.org/10.1128/IAI.00999-10>.
  15. Bai, Y., Yang, J., Zhou, X., Ding, X., Eisele, L.E., and Bai, G. (2012). *Mycobacterium tuberculosis* Rv3586 (DacA) is a diadenylate cyclase that converts ATP or ADP into c-di-AMP. *PLoS one* 7, e35206. <https://doi.org/10.1371/journal.pone.0035206>.
  16. Yang, J., Bai, Y., Zhang, Y., Gabrielle, V.D., Jin, L., and Bai, G. (2014). Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in *Mycobacterium tuberculosis* leads to reduced virulence in a mouse model of infection. *Mol. Microbiol.* 93, 65–79. <https://doi.org/10.1111/mmi.12641>.
  17. Dey, B., Dey, R.J., Cheung, L.S., Pokkali, S., Guo, H., Lee, J.H., and Bishai, W.R. (2015). A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. *Nat. Med.* 21, 401–406. <https://doi.org/10.1038/nm.3813>.
  18. Dey, R.J., Dey, B., Zheng, Y., Cheung, L.S., Zhou, J., Sayre, D., Kumar, P., Guo, H., Lamichhane, G., Sintim, H.O., and Bishai, W.R. (2017). Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase. *Nat. Chem. Biol.* 13, 210–217. <https://doi.org/10.1038/nchembio.2254>.
  19. Wassermann, R., Gulen, M.F., Sala, C., Perin, S.G., Lou, Y., Rybniker, J., Schmid-Burgk, J.L., Schmidt, T., Hornung, V., Cole, S.T., and Ablasser, A. (2015). *Mycobacterium tuberculosis* differentially activates cGAS- and inflammasome-dependent intracellular immune responses through ESX-1. *Cell host & microbe* 17, 799–810. <https://doi.org/10.1016/j.chom.2015.05.003>.
  20. Watson, R.O., Bell, S.L., MacDuff, D.A., Kimmey, J.M., Diner, E.J., Olivas, J., Vance, R.E., Stallings, C.L., Virgin, H.W., and Cox, J.S. (2015). The cytosolic sensor cGAS detects *Mycobacterium tuberculosis* DNA to induce type I interferons and activate autophagy. *Cell host & microbe* 17, 811–819. <https://doi.org/10.1016/j.chom.2015.05.004>.
  21. Brosch, R., Gordon, S.V., Garnier, T., Eiglmeier, K., Frigui, W., Valenti, P., Dos Santos, S., Duthoy, S., Lacroix, C., Garcia-Pelayo, C., et al. (2007). Genome plasticity of BCG and impact on vaccine efficacy. *Proc. Natl. Acad. Sci. United States America* 104, 5596–5601. <https://doi.org/10.1073/pnas.0700869104>.
  22. Pym, A.S., Brodin, P., Brosch, R., Huerre, M., and Cole, S.T. (2002). Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines *Mycobacterium bovis* BCG and *Mycobacterium microti*. *Mol. Microbiol.* 46, 709–717. <https://doi.org/10.1046/j.1365-2958.2002.03237.x>.
  23. Arbues, A., Aguilo, J.I., Gonzalo-Asensio, J., Marinova, D., Uranga, S., Puentes, E., Fernandez, C., Parra, A., Cardona, P.J., Vilaplana, C., et al. (2013). Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. *Vaccine* 31, 4867–4873. <https://doi.org/10.1016/j.vaccine.2013.07.051>.
  24. Brosset, E., Martin, C., and Gonzalo-Asensio, J. (2015). Evolutionary landscape of the *Mycobacterium tuberculosis* complex from the viewpoint of PhoPR: implications for virulence regulation and application to vaccine development. *mBio* 6, 01289–01215. <https://doi.org/10.1128/mBio.01289-15>.
  25. Frigui, W., Bottai, D., Majlessi, L., Monot, M., Josselin, E., Brodin, P., Garnier, T., Gicquel, B., Martin, C., Leclerc, C., et al. (2008). Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. *PLoS Pathog.* 4, e33. <https://doi.org/10.1371/journal.ppat.0040033>.
  26. Solans, L., Aguilo, N., Samper, S., Pawlik, A., Frigui, W., Martin, C., Brosch, R., and Gonzalo-Asensio, J. (2014). A specific polymorphism in *Mycobacterium tuberculosis* H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component. *Infect. Immun.* 82, 3446–3456. <https://doi.org/10.1128/IAI.01824-14>.
  27. Gonzalo Asensio, J., Maia, C., Ferrer, N.L., Barilone, N., Laval, F., Soto, C.Y., Winter, N., Daffe, M., Gicquel, B., Martin, C., and Jackson, M. (2006). The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in *Mycobacterium tuberculosis*. *J. Biol. Chem.* 281, 1313–1316. <https://doi.org/10.1074/jbc.C500388200>.
  28. Walters, S.B., Dubnau, E., Kolesnikova, I., Laval, F., Daffe, M., and Smith, I. (2006). The *Mycobacterium tuberculosis* PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. *Mol. Microbiol.* 60, 312–330. <https://doi.org/10.1111/j.1365-2958.2006.05102.x>.
  29. Solans, L., Gonzalo-Asensio, J., Sala, C., Benjak, A., Uplekar, S., Rougemont, J., Guilhot, C., Malaga, W., Martin, C., and Cole, S.T. (2014). The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in *Mycobacterium tuberculosis*. *PLoS Pathog.* 10, e1004183. <https://doi.org/10.1371/journal.ppat.1004183>.
  30. Sayes, F., Blanc, C., Ates, L.S., Deboosere, N., Orgeur, M., Le Chevalier, F., Groschel, M.I., Frigui, W., Song, O.R., Lo-Man, R., et al. (2018). Multiplexed quantitation of intraphagocyte *Mycobacterium tuberculosis* secreted protein effectors. *Cell Rep.* 23, 1072–1084. <https://doi.org/10.1016/j.celrep.2018.03.125>.
  31. Camacho, L.R., Ensergueix, D., Perez, E., Gicquel, B., and Guilhot, C. (1999). Identification of a virulence gene cluster of *Mycobacterium tuberculosis* by signature-tagged transposon mutagenesis. *Mol. Microbiol.* 34, 257–267. <https://doi.org/10.1046/j.1365-2958.1999.01593.x>.
  32. Groschel, M.I., Sayes, F., Shin, S.J., Frigui, W., Pawlik, A., Orgeur, M., Canetti, R., Honore, N., Simeone, R., van der Werf, T.S., et al. (2017). Recombinant BCG expressing ESX-1 of *Mycobacterium marinum* combines low virulence with cytosolic immune signaling and improved TB protection. *Cell Rep.* 18, 2752–2765. <https://doi.org/10.1016/j.celrep.2017.02.057>.
  33. Dey, R.J., Dey, B., Singh, A.K., Praharaj, M., and Bishai, W. (2020). *Bacillus calmette-guerin* overexpressing an endogenous stimulator of interferon genes agonist provides enhanced protection against pulmonary tuberculosis. *J. Infect. Dis.* 221, 1048–1056. <https://doi.org/10.1093/infdis/jiz116>.
  34. Ning, H., Wang, L., Zhou, J., Lu, Y., Kang, J., Ding, T., Shen, L., Xu, Z., and Bai, Y. (2019). Recombinant BCG with bacterial signaling molecule cyclic di-AMP as endogenous adjuvant induces elevated immune responses after *Mycobacterium tuberculosis* infection. *Front. Immunol.* 10, 1519. <https://doi.org/10.3389/fimmu.2019.01519>.
  35. Perez, I., Uranga, S., Sayes, F., Frigui, W., Samper, S., Arbues, A., Aguilo, N., Brosch, R., Martin, C., and Gonzalo-Asensio, J. (2020). Live attenuated TB vaccines representing the three modern *Mycobacterium tuberculosis* lineages reveal that the Euro-American genetic background confers optimal vaccine potential. *EBioMedicine* 55, 102761. <https://doi.org/10.1016/j.ebiom.2020.102761>.
  36. Zhang, Y., Yang, J., and Bai, G. (2018). Cyclic di-AMP-mediated interaction between *Mycobacterium tuberculosis* DeltacnpB and macrophages implicates a novel strategy for improving BCG vaccination. *Pathog. Dis.* 76. <https://doi.org/10.1093/femspd/fty008>.
  37. Aguilo, N., Gonzalo-Asensio, J., Alvarez-Arguedas, S., Marinova, D., Gomez, A.B., Uranga, S., Spallek, R., Singh, M., Audran, R., Spertini, F., and Martin, C. (2017). Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against *Mycobacterium tuberculosis*. *Nat. Commun.* 8, 16085. <https://doi.org/10.1038/ncomms16085>.
  38. Hsu, T., Hingley-Wilson, S.M., Chen, B., Chen, M., Dai, A.Z., Morin, P.M., Marks, C.B., Padiyar, J., Goulding, C., Gingery, M., et al. (2003). The primary mechanism of attenuation of *Bacillus Calmette-Guerin* is a loss of secreted lytic function required for invasion of lung interstitial tissue. *Proc. Natl. Acad. Sci. United States America* 100, 12420–12425. <https://doi.org/10.1073/pnas.1635213100>.

39. Stanley, S.A., Johndrow, J.E., Manzanillo, P., and Cox, J.S. (2007). The Type I IFN response to infection with *Mycobacterium tuberculosis* requires ESX-1-mediated secretion and contributes to pathogenesis. *J. Immunol.* *178*, 3143–3152. <https://doi.org/10.4049/jimmunol.178.5.3143>.
40. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed, S., Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H.G., et al. (2012). Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc. Natl. Acad. Sci. U S A* *109*, 17537–17542. <https://doi.org/10.1073/pnas.1202870109>.
41. Tarancon, R., Dominguez-Andres, J., Uranga, S., Ferreira, A.V., Groh, L.A., Domenech, M., Gonzalez-Camacho, F., Riksen, N.P., Aguilo, N., Yuste, J., et al. (2020). New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. *PLoS Pathog.* *16*, e1008404. <https://doi.org/10.1371/journal.ppat.1008404>.
42. Mayer-Barber, K.D., Andrade, B.B., Barber, D.L., Hieny, S., Feng, C.G., Caspar, P., Oland, S., Gordon, S., and Sher, A. (2011). Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during *Mycobacterium tuberculosis* infection. *Immunity* *35*, 1023–1034. <https://doi.org/10.1016/j.immuni.2011.12.002>.
43. Zhang, L., Ru, H.W., Chen, F.Z., Jin, C.Y., Sun, R.F., Fan, X.Y., Guo, M., Mai, J.T., Xu, W.X., Lin, Q.X., and Liu, J. (2016). Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. *Mol. Ther.* *24*, 398–405. <https://doi.org/10.1038/mt.2015.216>.
44. Martin, C., Marinova, D., Aguilo, N., and Gonzalo-Asensio, J. (2021). MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG. *Vaccine* *39*, 7277–7285. <https://doi.org/10.1016/j.vaccine.2021.06.049>.
45. Jenal, U., Reinders, A., and Lori, C. (2017). Cyclic di-GMP: second messenger extraordinaire. *Nat. Rev. Microbiol.* *15*, 271–284. <https://doi.org/10.1038/nrmicro.2016.190>.
46. Perez, E., Samper, S., Bordas, Y., Guilhot, C., Gicquel, B., and Martin, C. (2001). An essential role for *phoP* in *Mycobacterium tuberculosis* virulence. *Mol. Microbiol.* *41*, 179–187.
47. Gonzalo-Asensio, J., Malaga, W., Pawlik, A., Astarie-Dequeker, C., Passemar, C., Moreau, F., Laval, F., Daffe, M., Martin, C., Brosch, R., and Guilhot, C. (2014). Evolutionary history of tuberculosis shaped by conserved mutations in the *PhoPR* virulence regulator. *Proc. Natl. Acad. Sci. U S A* *111*, 11491–11496. <https://doi.org/10.1073/pnas.1406693111>.
48. Li, L., Yin, Q., Kuss, P., Maliga, Z., Millan, J.L., Wu, H., and Mitchison, T.J. (2014). Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs. *Nat. Chem. Biol.* *10*, 1043–1048. <https://doi.org/10.1038/nchembio.1661>.
49. Ablasser, A., Schmid-Burgk, J.L., Hemmerling, I., Horvath, G.L., Schmidt, T., Latz, E., and Hornung, V. (2013). Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. *Nature* *503*, 530–534. <https://doi.org/10.1038/nature12640>.
50. Devaux, L., Kaminski, P.A., Trieu-Cuot, P., and Firon, A. (2018). Cyclic di-AMP in host-pathogen interactions. *Curr. Opin. Microbiol.* *41*, 21–28. <https://doi.org/10.1016/j.mib.2017.11.007>.
51. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., and O'Garra, A. (2015). Type I interferons in infectious disease. *Nat. Rev. Immunol.* *15*, 87–103. <https://doi.org/10.1038/nri3787>.
52. Blanc, L., Gilleron, M., Prandi, J., Song, O.R., Jang, M.S., Gicquel, B., Drocourt, D., Neyrolles, O., Brodin, P., Tiraby, G., et al. (2017). *Mycobacterium tuberculosis* inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. *Proc. Natl. Acad. Sci. U S A* *114*, 11205–11210. <https://doi.org/10.1073/pnas.1707840114>.
53. Ruhl, C.R., Pasko, B.L., Khan, H.S., Kindt, L.M., Stamm, C.E., Franco, L.H., Hsia, C.C., Zhou, M., Davis, C.R., Qin, T., et al. (2020). *Mycobacterium tuberculosis* sulfolipid-1 activates nociceptive neurons and induces cough. *Cell* *181*, 293–305.e11. <https://doi.org/10.1016/j.cell.2020.02.026>.
54. Van Dis, E., Sogi, K.M., Rae, C.S., Sivick, K.E., Surh, N.H., Leong, M.L., Kanne, D.B., Metchette, K., Leong, J.J., Brumfiel, J.R., et al. (2018). STING-activating adjuvants elicit a Th17 immune response and protect against *Mycobacterium tuberculosis* infection. *Cell Rep.* *23*, 1435–1447. <https://doi.org/10.1016/j.celrep.2018.04.003>.
55. Jackson, M., Raynaud, C., Laneelle, M.A., Guilhot, C., Laurent-Winter, C., Ensergueix, D., Gicquel, B., and Daffe, M. (1999). Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the *Mycobacterium tuberculosis* cell envelope. *Mol. Microbiol.* *31*, 1573–1587. <https://doi.org/10.1046/j.1365-2958.1999.01310.x>.
56. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry, C.E., 3rd, et al. (1998). Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* *393*, 537–544. <https://doi.org/10.1038/31159>.
57. Brosch, R., Gordon, S.V., Billault, A., Garnier, T., Eiglmeier, K., Soravito, C., Barrell, B.G., and Cole, S.T. (1998). Use of a *Mycobacterium tuberculosis* H37Rv bacterial artificial chromosome library for genome mapping, sequencing, and comparative genomics. *Infect. Immun.* *66*, 2221–2229.
58. Datsenko, K.A., and Wanner, B.L. (2000). One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U S A* *97*, 6640–6645. <https://doi.org/10.1073/pnas.120163297>.
59. van Kessel, J.C., and Hatfull, G.F. (2007). Recombineering in *Mycobacterium tuberculosis*. *Nat. Methods* *4*, 147–152. <https://doi.org/10.1038/nmeth996>.
60. Corrigan, R.M., Abbott, J.C., Burhenne, H., Kaever, V., and Grundling, A. (2011). c-di-AMP is a new second messenger in *Staphylococcus aureus* with a role in controlling cell size and envelope stress. *PLoS Pathog.* *7*, e1002217. <https://doi.org/10.1371/journal.ppat.1002217>.